CG Oncology (CGON) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.64

Estimate

-$0.81

Surprise

+20.9%

Revenue (period 2026-09-30)

$1.6M

Score today

5.3/10

Revenue source: xbrl.

CG Oncology (CGON) reported a narrower loss than forecast — adjusted EPS of -$0.64 against the -$0.81 estimate (a 20.9% beat on a still-unprofitable quarter).

• 12 Health Care Stocks Moving In Friday's Intraday Session — benzinga, 2026-11-06
• CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates — fiscal.ai, 2026-11-06
• CG Oncology Q3 EPS $(0.64) Beats $(0.82) Estimate, Sales $1.604M Beat $643.584K Estimate — benzinga, 2026-11-06

TrendMatrix currently rates CGON Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +20.9% surprise compares with a -9.5% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$75.99

Price target

$79.24

Stop

$70.67

Upside to target

+4.3%

Reward-to-risk

0.3:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$6.74B

P/E (fwd)

-25.9

52-week range

$35.80–$80.97

Off 52-week high

6.2%

RSI (14)

77

Volume vs avg

3.40×

Score today

5.3/10